Medistim ASA

OB:MEDI Stock Report

Market Cap: kr3.3b

Medistim Management

Management criteria checks 3/4

Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 14.67 years. total yearly compensation is NOK7.21M, comprised of 42% salary and 58% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth NOK12.78M. The average tenure of the management team and the board of directors is 9.4 years and 1.3 years respectively.

Key information

Kari Krogstad

Chief executive officer

kr7.2m

Total compensation

CEO salary percentage42.0%
CEO tenure14.7yrs
CEO ownership0.4%
Management average tenure9.4yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04
Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

Nov 10
One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Dec 14
What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

Sep 06
Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Jun 14
A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Apr 21
Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Mar 31
Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Mar 05
Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 01
Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Jan 11
Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Medistim (OB:MEDI) Might Become A Compounding Machine

Sep 29
Medistim (OB:MEDI) Might Become A Compounding Machine

Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Sep 07
Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

May 17
Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Mar 19
Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 02
Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Feb 19
Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Jan 21
A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Dec 27
Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Dec 10
Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

Nov 23
Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

CEO Compensation Analysis

How has Kari Krogstad's remuneration changed compared to Medistim's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

kr103m

Dec 31 2023kr7mkr3m

kr104m

Sep 30 2023n/an/a

kr117m

Jun 30 2023n/an/a

kr116m

Mar 31 2023n/an/a

kr116m

Dec 31 2022kr9mkr3m

kr114m

Sep 30 2022n/an/a

kr98m

Jun 30 2022n/an/a

kr92m

Mar 31 2022n/an/a

kr93m

Dec 31 2021kr6mkr3m

kr91m

Sep 30 2021n/an/a

kr88m

Jun 30 2021n/an/a

kr84m

Mar 31 2021n/an/a

kr70m

Dec 31 2020kr6mkr3m

kr69m

Sep 30 2020n/an/a

kr71m

Jun 30 2020n/an/a

kr74m

Mar 31 2020n/an/a

kr75m

Dec 31 2019kr4mkr3m

kr70m

Sep 30 2019n/an/a

kr79m

Jun 30 2019n/an/a

kr73m

Mar 31 2019n/an/a

kr64m

Dec 31 2018kr4mkr2m

kr57m

Sep 30 2018n/an/a

kr46m

Jun 30 2018n/an/a

kr48m

Mar 31 2018n/an/a

kr45m

Dec 31 2017kr4mkr2m

kr48m

Compensation vs Market: Kari's total compensation ($USD655.55K) is about average for companies of similar size in the Norwegian market ($USD542.83K).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.

CEO

Kari Krogstad (59 yo)

14.7yrs

Tenure

kr7,205,702

Compensation

Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...

Leadership Team

NamePositionTenureCompensationOwnership
Kari Krogstad
CEO & President14.7yrskr7.21m0.39%
NOK 12.8m
Thomas Jakobsen
Chief Financial Officerno datakr2.77m0.17%
NOK 5.5m
Helge Borslid
Vice President of Operations & Manufacturingno datakr1.67mno data
Hæge Johanne Wetterhus
Vice President of Marketing13.8yrskr1.87m0.0087%
NOK 288.1k
Hakon Grothe
Chief Innovation Officer5.1yrskr1.91m0.043%
NOK 1.4m
Ole Eiksund
Chief Business Development Officer2.1yrskr1.68m0.032%
NOK 1.1m
Mike Farbelow
President of Medistim USA Incno datakr3.63m0.011%
NOK 360.3k
Roger Morberg
Vice President of Sales - APACno datakr2.55m0.089%
NOK 2.9m
Stephanie Stenhagen
Vice President of Sales EMEAno datakr1.79m0.015%
NOK 503.9k
Ole Robsrud
Managing Director of Medistim Norge ASno datakr1.83m0.019%
NOK 622.9k

9.4yrs

Average Tenure

59yo

Average Age

Experienced Management: MEDI's management team is seasoned and experienced (9.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oyvin Broymer
Chairman24.3yrskr495.00k7.02%
NOK 232.6m
Anna Ahlberg
Independent Director1.1yrsno datano data
Jon Hoem
Independent Director1.3yrsno datano data
Ole Dahlberg
Independent Director1.1yrsno datano data
Tove Raanes
Independent Director10.3yrskr300.00kno data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Board: MEDI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.